Indeed, WIP1 inhibitors, including GSK2830371 (GSK), are currently being pursued as anticancer drugs based on their ability to reactivate p53.27–29 We thus tested the effect of GSK on CSC properties in NSCLC cells. This evidence concerns the gene PPM1D and non-small cell lung carcinoma.